Valisure’s Benzene Testing Challenged By PCPC; FDA Focus Should Be Raw Materials, Trade Group Says
Executive Summary
On roughly the 1-year anniversary of Valisure’s citizen petition to the FDA regarding benzene detected in body sprays, the Personal Care Products Council weighs in on the matter.
You may also be interested in...
PCPC Challenges 2ppm Benzene Limit Cited By Valisure, Class Action Plaintiffs
In comments to the US FDA, PCPC provides a “highly conservative” risk assessment of benzene impurity in a dry shampoo product, showing that “even a benzene concentration of 15 ppm in a hypothetical aerosol dry shampoo product would have an acceptable level of risk for a lifetime of daily use.” The exercise was undertaken in response to Valisure’s petition for FDA regulatory action on benzene-tainted dry shampoos.
Ranitidine Cancer Risk Found Only By Litigation Plaintiffs’ ‘Unreliable’ Research, Judge Rules
Plaintiffs in Multi-District Litigation didn’t provide scientific evidence of OTC heartburn drug Zantac increasing risk of cancer. Federal judge says plaintiffs' research showed “a lack of substantiation for analytical leaps” in alleging dangerously high levels of NDMA in ranitidine drugs.
Valisure Alerts US FDA To Benzene In Dry Shampoos, Says Any Detected Level Could Be ‘Unacceptable’
Valisure found 70% of 148 tested dry shampoo batches contained ‘quantifiable’ benzene. The US FDA advises a strict 2ppm limit when benzene’s use is unavoidable to produce a drug product with a “significant therapeutic advance.” In dry shampoos, “any significant detection of benzene could be deemed unacceptable,” Valisure suggests in its 31 October citizen petition to the agency.